At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Erlotinib +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer
In Brief
A Phase 2 clinical trial evaluating Erlotinib, Bevacizumab, and 5 other interventions for Esophageal Cancer. Completed, enrolled 62 participants across 9 sites.
Detailed Summary
The purpose of this study is to see if adding two targeted drugs (bevacizumab and erlotinib) further improves the response to chemotherapy (5-FU, paclitaxel, carboplatin) and radiation therapy in patients with operable esophageal cancer. Side effects (toxicity) information will also be collected.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartFeb 2007
Primary CompletionSep 2009
Study CompletionAug 2011
TodayJul 2026
First PostedOct 26, 2006
Enrollment StartFeb 1, 2007
Primary CompletionSep 1, 2009
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.7 years ago
Interventions
Erlotinibdrug
Erlotinib
Bevacizumabdrug
Bevacizumab
Paclitaxeldrug
Paclitaxel
Carboplatindrug
Carboplatin
5-FUdrug
5-FU
Radiation therapyprocedure
Radiation therapy
Surgeryprocedure
Surgery